Amneal Pharmaceuticals (AMRX) Free Cash Flow (2017 - 2026)

Amneal Pharmaceuticals' Free Cash Flow history runs 10 years deep, the most recent figure standing at -$34.9 million for Q1 2026.

• In Q1 2026, Free Cash Flow fell 506.85% year-over-year to -$34.9 million; the TTM figure through Mar 2026 stood at $240.8 million (down 4.09% YoY), while the FY2025 annual figure was $269.9 million, up 11.0% from the prior year.
• Free Cash Flow was -$34.9 million for Q1 2026 at Amneal Pharmaceuticals, down from $108.5 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $130.0 million in Q1 2023 to a low of -$130.6 million in Q2 2022.
• Historically, Free Cash Flow has averaged $47.0 million across 5 years, with a median of $69.7 million in 2023.
• The sharpest annual moves came in 2023 and 2026: Free Cash Flow soared 462.39% in 2023, then sank 506.85% in 2026.
• A 5-year view of Free Cash Flow shows it stood at -$34.8 million in 2022, then jumped by 462.39% to $126.0 million in 2023, then fell by 18.29% to $102.9 million in 2024, then rose by 5.46% to $108.5 million in 2025, then sank by 132.17% to -$34.9 million in 2026.
• The last three Free Cash Flow figures came in at -$34.9 million (Q1 2026), $108.5 million (Q4 2025), and $106.2 million (Q3 2025), per Business Quant data.